Opioid-Induced Bowel Dysfunction (OBD or OIBD) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Opioid-Induced Bowel Dysfunction (OBD or OIBD) – Pipeline Review, H1 2017’, provides an overview of the Opioid-Induced Bowel Dysfunction (OBD or OIBD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Opioid-Induced Bowel Dysfunction (OBD or OIBD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Opioid-Induced Bowel Dysfunction (OBD or OIBD)

The report reviews pipeline therapeutics for Opioid-Induced Bowel Dysfunction (OBD or OIBD) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Opioid-Induced Bowel Dysfunction (OBD or OIBD) therapeutics and enlists all their major and minor projects

The report assesses Opioid-Induced Bowel Dysfunction (OBD or OIBD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Opioid-Induced Bowel Dysfunction (OBD or OIBD)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Opioid-Induced Bowel Dysfunction (OBD or OIBD)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Opioid-Induced Bowel Dysfunction (OBD or OIBD) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ChironWells GmbH

RaQualia Pharma Inc

Vitality Biopharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Overview

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Companies Involved in Therapeutics Development

ChironWells GmbH

RaQualia Pharma Inc

Vitality Biopharma Inc

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Drug Profiles

ORP-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ORP-106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RQ-00433412 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Mu Opioid Receptor for Gastrointestinal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Opioid-Induced Bowel Dysfunction (OBD or OIBD), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Opioid-Induced Bowel Dysfunction (OBD or OIBD) – Pipeline by ChironWells GmbH, H1 2017

Opioid-Induced Bowel Dysfunction (OBD or OIBD) – Pipeline by RaQualia Pharma Inc, H1 2017

Opioid-Induced Bowel Dysfunction (OBD or OIBD) – Pipeline by Vitality Biopharma Inc, H1 2017

Opioid-Induced Bowel Dysfunction (OBD or OIBD) – Dormant Projects, H1 2017

List of Figures

List of Figures

Number of Products under Development for Opioid-Induced Bowel Dysfunction (OBD or OIBD), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports